[go: up one dir, main page]

MX2018011293A - Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. - Google Patents

Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.

Info

Publication number
MX2018011293A
MX2018011293A MX2018011293A MX2018011293A MX2018011293A MX 2018011293 A MX2018011293 A MX 2018011293A MX 2018011293 A MX2018011293 A MX 2018011293A MX 2018011293 A MX2018011293 A MX 2018011293A MX 2018011293 A MX2018011293 A MX 2018011293A
Authority
MX
Mexico
Prior art keywords
cysteamine
prolonged release
salt
pharmaceutical composition
release pharmaceutical
Prior art date
Application number
MX2018011293A
Other languages
English (en)
Other versions
MX387263B (es
Inventor
Gazzaniga Andrea
Cerea Matteo
Maroni Alessandra
BARCHIELLI Marco
Original Assignee
Recordati Ind Chimica E Farmaceutica S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ind Chimica E Farmaceutica S P A filed Critical Recordati Ind Chimica E Farmaceutica S P A
Publication of MX2018011293A publication Critical patent/MX2018011293A/es
Publication of MX387263B publication Critical patent/MX387263B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una forma de dosificación de unidad múltiple de liberación prolongada, preferiblemente perlas, de cisteamina, cistamina o una sal farmacéuticamente aceptable de la misma, preferiblemente bitartrato de cisteamina, con un recubrimiento no gastro resistente. La forma de dosis está particularmente indicada para la administración a pacientes una o dos veces al día y puede ser utilizada también para administración pediátrica.
MX2018011293A 2016-03-18 2017-03-14 Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma. MX387263B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUA2016A001799A ITUA20161799A1 (it) 2016-03-18 2016-03-18 Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
PCT/EP2017/055964 WO2017157922A1 (en) 2016-03-18 2017-03-14 Prolonged release pharmaceutical composition comprising cysteamine or salt thereof

Publications (2)

Publication Number Publication Date
MX2018011293A true MX2018011293A (es) 2019-02-13
MX387263B MX387263B (es) 2025-03-18

Family

ID=56203798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011293A MX387263B (es) 2016-03-18 2017-03-14 Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma.

Country Status (13)

Country Link
US (1) US11135173B2 (es)
EP (1) EP3429565B1 (es)
JP (1) JP2019508441A (es)
KR (1) KR102361246B1 (es)
AU (1) AU2017234169B2 (es)
CO (1) CO2018009543A2 (es)
EA (1) EA201891860A1 (es)
ES (1) ES2879810T3 (es)
IL (1) IL261087B (es)
IT (1) ITUA20161799A1 (es)
MX (1) MX387263B (es)
UA (1) UA123782C2 (es)
WO (1) WO2017157922A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
IT201700064875A1 (it) * 2017-06-12 2018-12-12 Sicit 2000 Spa Sistemi multistrato idrorepellenti a rilascio controllato di principi attivi in acqua e nel terreno.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US6733783B2 (en) * 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20050004075A1 (en) * 2000-12-13 2005-01-06 Walcom Animal Science (I.P.2) Limited Composition for regulating animal growth, method of manufacture and use thereof
CN100391448C (zh) * 2003-11-19 2008-06-04 奥加生物药业(I.P.1)有限公司 提高乙醇代谢和减轻宿醉效应的物质和方法
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
ES2774755T3 (es) * 2006-01-27 2020-07-22 Univ California Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
ATE525065T1 (de) * 2006-07-10 2011-10-15 Pfleger R Chem Fab Pharmazeutische zubereitung für die orale verabreichung mit gesteuerter wirkstofffreisetzung im dünndarm und verfahren zu ihrer herstellung
DK2214480T3 (da) * 2007-11-30 2013-07-08 Univ California Fremgangsmåder til behandling af nonalkoholisk steatohepatitis (NASH) ved anvendelse af cysteaminprodukter
CN101653426A (zh) * 2009-09-16 2010-02-24 冯利萍 一种高稳型半胱胺盐酸盐的缓释小丸及制备方法
MX2012007448A (es) 2009-12-22 2012-09-12 Abbott Healthcare Private Ltd Composicion farmaceutica de liberacion controlada.
KR20140125644A (ko) * 2013-04-19 2014-10-29 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈 종양 전이의 저해에 있어서의 시스테아민 및 그의 유도체의 용도
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella

Also Published As

Publication number Publication date
BR112018068155A2 (pt) 2019-02-12
UA123782C2 (uk) 2021-06-02
AU2017234169B2 (en) 2023-01-12
ES2879810T3 (es) 2021-11-23
WO2017157922A1 (en) 2017-09-21
KR102361246B1 (ko) 2022-02-09
AU2017234169A1 (en) 2018-08-16
CO2018009543A2 (es) 2018-10-10
MX387263B (es) 2025-03-18
EA201891860A1 (ru) 2019-02-28
EP3429565B1 (en) 2021-06-09
KR20180120268A (ko) 2018-11-05
US20190076368A1 (en) 2019-03-14
EP3429565A1 (en) 2019-01-23
CA3013429A1 (en) 2017-09-21
JP2019508441A (ja) 2019-03-28
US11135173B2 (en) 2021-10-05
IL261087B (en) 2021-10-31
ITUA20161799A1 (it) 2017-09-18
IL261087A (en) 2018-10-31

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
JP2015057451A5 (es)
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
JP2017506624A5 (es)
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CO2019003808A2 (es) Composición farmacéutica que comprende antagonista receptor de mineralocorticoides y uso de la misma
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
IL275091B1 (en) Methods for treating gaucher disease
MX2015009681A (es) Un medicamento combinado que comprende finilefrina y paracetamol.
AR108792A1 (es) Composiciones que comprenden timolol
HRP20171305T1 (hr) Upotreba odiparcila u liječenju mukopolisaharidoze
JP2019529554A5 (es)
MX2022000418A (es) Composicion farmaceutica de imatinib.
CO2019013645A2 (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
CY1120693T1 (el) Συνδυασμος ενος αναστολεα κινασης ρι3 με πακλιταξελη για χρηση στη θεραπεια ή προληψη ενος καρκινου κεφαλης και τραχηλου